GALAPAGOS NV/S (NASDAQ:GLPG) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday, February 25th.
GLPG has been the topic of a number of other research reports. Credit Suisse Group upgraded GALAPAGOS NV/S from a “neutral” rating to an “outperform” rating in a research report on Thursday, December 13th. Morgan Stanley increased their target price on GALAPAGOS NV/S from $127.00 to $131.00 and gave the company an “overweight” rating in a research note on Monday, November 5th. ValuEngine raised GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Raymond James began coverage on GALAPAGOS NV/S in a research note on Wednesday, November 14th. They set a “strong-buy” rating and a $157.00 price objective on the stock. Finally, Zacks Investment Research cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. GALAPAGOS NV/S presently has an average rating of “Buy” and an average target price of $123.64.
Shares of GLPG stock traded down $3.09 during trading on Monday, hitting $99.47. The company’s stock had a trading volume of 39,448 shares, compared to its average volume of 78,848. The firm has a market cap of $5.25 billion, a PE ratio of -37.68 and a beta of 1.65. GALAPAGOS NV/S has a 52 week low of $85.00 and a 52 week high of $122.28.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. We Are One Seven LLC purchased a new position in shares of GALAPAGOS NV/S during the 4th quarter valued at $27,000. Financial Gravity Wealth Inc. lifted its stake in GALAPAGOS NV/S by 64.1% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 2,261 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 883 shares in the last quarter. Trexquant Investment LP purchased a new stake in GALAPAGOS NV/S in the 3rd quarter worth $256,000. Financial Gravity Companies Inc. purchased a new stake in shares of GALAPAGOS NV/S during the 4th quarter valued at about $233,000. Finally, Townsquare Capital LLC purchased a new stake in shares of GALAPAGOS NV/S during the 4th quarter valued at about $279,000. Institutional investors own 15.73% of the company’s stock.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: Dividend Aristocrat Index
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.